Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01409733

TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients

Sponsor: Heidelberg University

Conditions Stage IV Melanoma Patients With Unresectable Liver Metastases

Interventions TACE using Drug Eluting Beads loaded with Doxorubicin

Updated 6 times since 2017 Last updated: Aug 3, 2011 Started: Jun 30, 2010 Primary completion: Sep 30, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Stage IV Melanoma Patients With Unresectable Liver Metastases and is currently ongoing. Heidelberg University leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2021 — Jun 2022 [monthly]

Unknown Status PHASE1_PHASE2
Feb 2017 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heidelberg University
SLK Kliniken Heilbronn GmbH
University Hospital Tuebingen

Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heilbronn, Germany